FDA Officials Explain Why They Paused Chikungunya Vaccination for Older Adults

FDA Officials Explain Why They Paused Chikungunya Vaccination for Older Adults

Federal officials paused administration of a vaccine against the chikungunya virus for some adults because post-vaccination problems may be related to the shot, regulatory authorities said on June 5. Seventeen serious adverse events—including two deaths—had been reported by early May among people who received the chikungunya vaccine. “FDA’s pause is intended to allow the agency time to adjudicate these events and ascertain whether additional, un…

FDA's Prasad explains rationale behind pausing Valneva's chikungunya vaccine in seniors

The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal relationship between the vaccine and ...